CUMBERLAND PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
CPIX$5.30-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three months ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Net revenues | $9,131,317 | $11,713,055 |
| Costs and expenses: | ||
| Cost of products sold | 1,933,889 | 1,425,714 |
| Selling and marketing | 5,064,875 | 4,231,980 |
| Research and development | 1,458,436 | 1,295,076 |
| General and administrative | 2,554,475 | 2,463,008 |
| Amortization | 1,248,934 | 1,005,330 |
| Total costs and expenses | 12,260,609 | 10,421,108 |
| Operating income (loss) | (3,129,292) | 1,291,947 |
| Interest income | 78,031 | 125,709 |
| Interest expense | (85,839) | (163,802) |
| Income (loss) before income taxes | (3,137,100) | 1,253,854 |
| Income tax expense | (3,871) | (5,670) |
| Co-commercialization investment loss | (146,080) | — |
| Net income (loss) | (3,287,051) | 1,248,184 |
| Net loss (income) at subsidiary attributable to noncontrolling interests | (2,588) | 8,884 |
| Net income (loss) attributable to common shareholders | $(3,289,639) | $1,257,068 |
| Income (loss) per share attributable to common shareholders | ||
| - basic | $(0.22) | $0.08 |
| - diluted | $(0.22) | $0.08 |
| Weighted-average shares outstanding | ||
| - basic | 14,960,210 | 14,942,522 |
| - diluted | 14,960,210 | 15,259,824 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.